Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315250 · ClinicalTrials.gov registry record · Phase 2
Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease
A Phase 2 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
NCT00315250 is a Phase 2 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 225 participants.
The verdict
NCT00315250, a Phase 2 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
Study Summary
We propose to build on preliminary data evaluating non-dopaminergic/non-motor clinical biomarkers to more fully assess these markers at the threshold of Parkinson disease (PD). Development of reliable biomarkers for both dopaminergic and non-dopaminergic manifestations of Parkinson disease (PD) and related disorders may dramatically accelerate research on PD etiology, pathophysiology, and therapeutics. Biomarkers are broadly defined as characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. Specific biomarkers may be useful at the onset of neurodegeneration, the onset of disease, and/or to mark disease progression.
Interventions
- DRUG [123I]β-CIT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2006-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00315250
The ClinicalTrials.gov registry entry for NCT00315250 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [123I]β-CIT is the first listed.
NCT00315250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00315250 about?
NCT00315250 is a clinical study titled "Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease". We propose to build on preliminary data evaluating non-dopaminergic/non-motor clinical biomarkers to more fully assess these markers at the threshold of Parkinson disease (PD). Development of reliable biomarkers for both dopaminergic and non-dopaminergic manifestations of Parkinson disease (PD) and...
What is the current status of trial NCT00315250?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2006-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00315250?
The interventions under investigation include: [123I]β-CIT (DRUG).
Who is sponsoring clinical trial NCT00315250?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.